The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study.
Children’s eating habits are strongly influenced by their parents' weight status, with those having overweight or obese ...
The drugmaker’s financial forecasts topped Wall Street’s expectations, reassuring investors after it overestimated demand for ...
Eli Lilly's profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...
Stay updated on the latest stock market trends and company earnings. Discover the impact of market gains and profit reports ...
Eli Lilly & Co.’s full-year earnings forecast came in line with analysts’ estimates as the company works to fix inventory problems with its new blockbuster obesity and diabetes drugs that weighed on ...
WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...
Wave Life Sciences (WVE) announced clinical trial application, CTA, approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in ...
Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.
€80M EU-funded Projects Launch Unprecedented Collaboration to Address the Obesity Crisis in Europe
Over the past decades, obesity has reached epidemic proportions, now affecting more than 1 billion people worldwide.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback